Abstract: The invention pertains to construction of next-generation DNA sequencing (NGS) libraries for whole genome sequencing, targeted resequencing, sequencing-based screening assays, metagenomics, or any other application requiring sample preparation for NGS.
Abstract: The invention can be used to provide a more efficient and less error-prone method of detecting variants in DNA, such as SNPs and indels. The invention also provides a method for performing inexpensive multiplex assays. The invention also provides methods for detection of DNA sequences altered after cleavage by a targetable endonuclease, such as the CRISPR Cas9 protein from the bacterium Streptococcus pyogenes.
Type:
Grant
Filed:
April 13, 2017
Date of Patent:
January 5, 2021
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Joseph Dobosy, Caifu Chen, Mark Aaron Behlke, Garrett Richard Rettig
Abstract: The invention describes composition and methods of use for novel hairpin blocked-cleavable primers. In one embodiment unblocking occurs through action of RNase H2. The method improves the specificity of PCR and reduces primer dimer events, enabling higher level multiplex reactions. Additionally, the invention protects RNA-containing primers from attack by single-strand RNases.
Type:
Grant
Filed:
August 29, 2017
Date of Patent:
December 8, 2020
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Joseph A. Walder, Joseph Dobosy, Mark Aaron Behlke
Abstract: Disclosed herein are nucleic acid-based data storage systems and nucleic acid data storage constructs comprising reusable nucleic acid sequences, each representing information carried by a single bit (and, in some embodiments, one or more adjacent bits) within a bit string, and each furthermore representing the position of the single bit within the bit string. Also described are methods for storing data in the nucleic acid-based data storage systems and nucleic acid data storage constructs of the disclosure.
Type:
Grant
Filed:
October 27, 2017
Date of Patent:
November 17, 2020
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Joseph Alan Walder, Jeffrey A. Manthey, William E. Martin, III, Shawn Allen
Abstract: This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA and tracrRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA and tracrRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRISPR Cas9 endonuclease system.
Type:
Grant
Filed:
October 21, 2016
Date of Patent:
September 8, 2020
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Michael Allen Collingwood, Ashley Mae Jacobi, Garrett Richard Rettig, Mollie Sue Schubert, Mark Aaron Behlke
Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.
Type:
Grant
Filed:
October 10, 2017
Date of Patent:
July 21, 2020
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Christopher Anthony Vakulskas, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
Abstract: The invention pertains to construction of next-generation DNA sequencing (NGS) libraries for whole genome sequencing, targeted resequencing, sequencing-based screening assays, metagenomics, or any other application requiring sample preparation for NGS.
Abstract: The present invention relates to a rapid detection of microbial-associated nuclease activity with chemically modified nuclease (e.g., ribonuclease) substrates, and probes and compositions useful in detection assays.
Type:
Grant
Filed:
February 10, 2017
Date of Patent:
May 19, 2020
Assignees:
University of Iowa Research Foundation, Integrated DNA Technologies, Inc.
Inventors:
James O. McNamara, II, Katie R. Flenker, Lingyan Huang, Alexander R. Horswill, Mark A. Behlke, Frank J. Hernandez
Abstract: The invention is directed to modified oligonucleotide compositions and methods for selectively reducing unwanted nucleic acid contaminants and enriching for desired nucleic acid targets from complex genomic nucleic acid mixtures for sequencing applications. The modified oligonucleotide compositions include one or more modified groups that increase the Tm of the resultant oligonucleotide composition.
Type:
Grant
Filed:
July 3, 2013
Date of Patent:
April 23, 2019
Assignees:
ROCHE FINANCE LTD, INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Mark Aaron Behlke, John Robert Havens, Mirna Jarosz, Zachary Zwirko, Doron Lipson, Frank Soo Juhn
Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
Type:
Grant
Filed:
December 21, 2017
Date of Patent:
March 19, 2019
Assignees:
CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
John J. Rossi, Mark A. Behlke, Dongho Kim
Abstract: Methods and compositions are provided for improving specificity during amplification of a target DNA sequence. The methods and compositions rely upon the use of an RNase H enzyme, a polymerase, and RNase H enzyme-sensitive, blocked-cleavable oligonucleotide primers in the amplification reactions, wherein the reaction mixtures include either an optimized final concentration of a divalent metal salt comprising 2.0 mM or less of free Mg++ cation and/or an optimized final concentration of a non-ionic detergent comprising at least about 0.001% polyethylene glycol hexadecyl ether.
Type:
Grant
Filed:
December 2, 2013
Date of Patent:
March 12, 2019
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Joseph Alan Walder, Mark Aaron Behlke, Scott D. Rose, Joseph R. Dobosy, Susan M. Rupp
Abstract: This invention pertains to improved methods for the synthesis of long, double stranded nucleic acid sequences containing difficult to clone or variable regions.
Abstract: The invention pertains to construction of next-generation DNA sequencing (NGS) libraries for whole genome sequencing, targeted resequencing, sequencing-based screening assays, metagenomics, or any other application requiring sample preparation for NGS.
Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
Type:
Grant
Filed:
December 12, 2016
Date of Patent:
October 23, 2018
Assignees:
CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
John J. Rossi, Mark A. Behlke, Dongho Kim
Abstract: The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.
Type:
Grant
Filed:
November 23, 2016
Date of Patent:
October 2, 2018
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Mark Aaron Behlke, Richard Owczarzy, Yong You, Joseph Alan Walder, Kim Lennox
Abstract: This invention pertains to the creation of a complex pool of adapters that contain complementary barcodes to be utilized in next generation sequencing library prep methods and methods of using barcoded adapters for next generation sequencing.
Abstract: The invention pertains to construction of next-generation DNA sequencing (NGS) libraries for whole genome sequencing, targeted resequencing, sequencing-based screening assays, metagenomics, or any other application requiring sample preparation for NGS.
Abstract: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.
Type:
Grant
Filed:
June 13, 2016
Date of Patent:
June 5, 2018
Assignees:
City of Hope, Integrated DNA Technologies, Inc.
Inventors:
John J. Rossi, Mark A. Behlke, Dongho Kim
Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
Type:
Application
Filed:
December 21, 2017
Publication date:
May 24, 2018
Applicants:
CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.